Treatment of cervical dystonia with botulinum toxin
Identifieur interne :
000A85 ( PascalFrancis/Curation );
précédent :
000A84;
suivant :
000A86
Treatment of cervical dystonia with botulinum toxin
Auteurs : Joseph Jankovic [
États-Unis]
Source :
-
Movement disorders [ 0885-3185 ] ; 2004.
RBID : Pascal:04-0228898
Descripteurs français
English descriptors
Abstract
Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double-blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 19 |
|---|
| A06 | | | | @3 SUP8 |
|---|
| A08 | 01 | 1 | ENG | @1 Treatment of cervical dystonia with botulinum toxin |
|---|
| A09 | 01 | 1 | ENG | @1 Basic and Therapeutic Aspects of Neurotoxins |
|---|
| A11 | 01 | 1 | | @1 JANKOVIC (Joseph) |
|---|
| A12 | 01 | 1 | | @1 BIGALKE (HANS) @9 ed. |
|---|
| A12 | 02 | 1 | | @1 DRESSLER (Dirk) @9 ed. |
|---|
| A12 | 03 | 1 | | @1 JANKOVIC (Joseph) @9 ed. |
|---|
| A14 | 01 | | | @1 Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 1 aut. |
|---|
| A15 | 01 | | | @1 Institute of Toxicology, Medical School of Hannover @2 Hannover @3 DEU @Z 1 aut. |
|---|
| A15 | 02 | | | @1 Department of Neurology, Rostock University @2 Rostock @3 DEU @Z 2 aut. |
|---|
| A15 | 03 | | | @1 Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 3 aut. |
|---|
| A20 | | | | @1 109-115 |
|---|
| A21 | | | | @1 2004 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000113591720150 |
|---|
| A44 | | | | @0 0000 @1 © 2004 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 74 ref. |
|---|
| A47 | 01 | 1 | | @0 04-0228898 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double-blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated. |
|---|
| C02 | 01 | X | | @0 002B17 |
|---|
| C03 | 01 | X | FRE | @0 Dystonie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Dystonia @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Distonía @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Traitement @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Treatment @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Tratamiento @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Bontoxilysin @2 FE @2 FR @5 03 |
|---|
| C03 | 03 | X | ENG | @0 Bontoxilysin @2 FE @2 FR @5 03 |
|---|
| C03 | 03 | X | SPA | @0 Bontoxilysin @2 FE @2 FR @5 03 |
|---|
| C03 | 04 | X | FRE | @0 Système nerveux pathologie @5 04 |
|---|
| C03 | 04 | X | ENG | @0 Nervous system diseases @5 04 |
|---|
| C03 | 04 | X | SPA | @0 Sistema nervioso patología @5 04 |
|---|
| C07 | 01 | X | FRE | @0 Metalloendopeptidases @2 FE |
|---|
| C07 | 01 | X | ENG | @0 Metalloendopeptidases @2 FE |
|---|
| C07 | 01 | X | SPA | @0 Metalloendopeptidases @2 FE |
|---|
| C07 | 02 | X | FRE | @0 Peptidases @2 FE |
|---|
| C07 | 02 | X | ENG | @0 Peptidases @2 FE |
|---|
| C07 | 02 | X | SPA | @0 Peptidases @2 FE |
|---|
| C07 | 03 | X | FRE | @0 Hydrolases @2 FE |
|---|
| C07 | 03 | X | ENG | @0 Hydrolases @2 FE |
|---|
| C07 | 03 | X | SPA | @0 Hydrolases @2 FE |
|---|
| C07 | 04 | X | FRE | @0 Enzyme @2 FE |
|---|
| C07 | 04 | X | ENG | @0 Enzyme @2 FE |
|---|
| C07 | 04 | X | SPA | @0 Enzima @2 FE |
|---|
| C07 | 05 | X | FRE | @0 Extrapyramidal syndrome @5 37 |
|---|
| C07 | 05 | X | ENG | @0 Extrapyramidal syndrome @5 37 |
|---|
| C07 | 05 | X | SPA | @0 Extrapiramidal síndrome @5 37 |
|---|
| C07 | 06 | X | FRE | @0 Mouvement involontaire @5 38 |
|---|
| C07 | 06 | X | ENG | @0 Involuntary movement @5 38 |
|---|
| C07 | 06 | X | SPA | @0 Movimiento involuntario @5 38 |
|---|
| C07 | 07 | X | FRE | @0 Muscle strié pathologie @5 39 |
|---|
| C07 | 07 | X | ENG | @0 Striated muscle disease @5 39 |
|---|
| C07 | 07 | X | SPA | @0 Músculo estriado patología @5 39 |
|---|
| C07 | 08 | X | FRE | @0 Trouble neurologique @5 40 |
|---|
| C07 | 08 | X | ENG | @0 Neurological disorder @5 40 |
|---|
| C07 | 08 | X | SPA | @0 Trastorno neurológico @5 40 |
|---|
| C07 | 09 | X | FRE | @0 Encéphale pathologie @5 41 |
|---|
| C07 | 09 | X | ENG | @0 Cerebral disorder @5 41 |
|---|
| C07 | 09 | X | SPA | @0 Encéfalo patología @5 41 |
|---|
| C07 | 10 | X | FRE | @0 Système nerveux central pathologie @5 42 |
|---|
| C07 | 10 | X | ENG | @0 Central nervous system disease @5 42 |
|---|
| C07 | 10 | X | SPA | @0 Sistema nervosio central patología @5 42 |
|---|
| N21 | | | | @1 145 |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Toxins 2002. Conference @3 Hannover DEU @4 2002 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002236
Links to Exploration step
Pascal:04-0228898
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment of cervical dystonia with botulinum toxin</title>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0228898</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0228898 INIST</idno>
<idno type="RBID">Pascal:04-0228898</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002236</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A85</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment of cervical dystonia with botulinum toxin</title>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14><country>États-Unis</country>
</affiliation><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004">2004</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Dystonia</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dystonie</term>
<term>Traitement</term>
<term>Bontoxilysin</term>
<term>Système nerveux pathologie</term>
</keywords><front><div type="abstract" xml:lang="en">Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double-blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA06><s3>SUP8</s3>
</fA06><fA08 i1="01" i2="1" l="ENG"><s1>Treatment of cervical dystonia with botulinum toxin</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>Basic and Therapeutic Aspects of Neurotoxins</s1>
</fA09><fA11 i1="01" i2="1"><s1>JANKOVIC (Joseph)</s1>
</fA11><fA12 i1="01" i2="1"><s1>BIGALKE (HANS)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="02" i2="1"><s1>DRESSLER (Dirk)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="03" i2="1"><s1>JANKOVIC (Joseph)</s1>
<s9>ed.</s9>
</fA12><fA14 i1="01"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14><fA15 i1="01"><s1>Institute of Toxicology, Medical School of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA15><fA15 i1="02"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA15><fA15 i1="03"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA15><fA20><s1>109-115</s1>
</fA20><fA21><s1>2004</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113591720150</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>74 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>04-0228898</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double-blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated.</s0>
</fC01><fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Distonía</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>04</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07><fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07><fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07><fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07><fC07 i1="06" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07><fC07 i1="06" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07><fC07 i1="06" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07><fC07 i1="07" i2="X" l="FRE"><s0>Muscle strié pathologie</s0>
<s5>39</s5>
</fC07><fC07 i1="07" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>39</s5>
</fC07><fC07 i1="07" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>39</s5>
</fC07><fC07 i1="08" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07><fC07 i1="08" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07><fC07 i1="08" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07><fC07 i1="09" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>41</s5>
</fC07><fC07 i1="09" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07><fC07 i1="09" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07><fC07 i1="10" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>42</s5>
</fC07><fC07 i1="10" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07><fC07 i1="10" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07><fN21><s1>145</s1>
</fN21><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Toxins 2002. Conference</s1>
<s3>Hannover DEU</s3>
<s4>2002</s4>
</fA30>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000A85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:04-0228898
|texte= Treatment of cervical dystonia with botulinum toxin
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
